<DOC>
	<DOCNO>NCT02709031</DOCNO>
	<brief_summary>Cicletanine , approve launched hypertension France Germany , promise beyond hypertension critically-unmet need diabetes . It evident vitro , animal human study cicletanine 's optimal dose diabetes challenge , critically-unmet need likely high hypertension . Cicletanine 's maximum tolerate dosage know , drug 's dose-limiting effect document potassium loss sodium loss thiazide-type activity ( one therapeutic mechanism drug know ) ; thiazide-type loss know reverse safely magnesium . This trial explore ability magnesium enhance cicletanine safety high dose trial involve patient hypertension complicate diabetes .</brief_summary>
	<brief_title>Cicletanine Hypertension With Diabetes : Added Magnesium Preserves Potassium Sodium</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Hypokalemia</mesh_term>
	<mesh_term>Potassium Deficiency</mesh_term>
	<mesh_term>Cicletanine</mesh_term>
	<criteria>1 . Sitting SBP ( systolic blood pressure ) &gt; 150 mmHg ( millimeter mercury ) five minute ' rest . 2 . Type II diabetes , HbA1c 8.5 11.5 % . If patient screen present outside range , investigator may elect rescreen patient determine patient 's eligibility . 3 . Age &gt; 18 &lt; 80 year age 4 . BMI 20 35 , inclusive 5 . Have stable exist therapy least 30 day prior initiation cicletanine ( Visit 2 ) a. change antihypertensive antihyperglycemia agent dose within 30 day prior screen visit . 6 . Willing comply requirement protocol . 7 . Willing provide write Informed Consent participate study approve appropriately constitute IRB ( Institutional Review Board ) . 8 . All female postmenopausal use least two form contraception entire study . 1 . Use potassium supplementation past 30 day 2 . Use potassiumwasting diuretic , e. g. , thiazide past 30 day 3 . AST ( aspartate aminotransferase ; also abbreviate SGOT ) outside normal range 5 40 mg/dL inclusive 4 . ALT ( alanine aminotransferase ; also abbreviate SGPT ) outside normal range 7 56 mg/dL inclusive 5 . Laboratory finding outside normal range consider ground exclusion discretion Sponsor , Medical Monitor / Principal Investigator 6 . History positive laboratory test HIV , HBV ( hepatitis B virus ) HCV ( hepatitis C virus ) 7 . Clinically significant psychiatric , addictive neurologic disease condition , Investigator 's opinion , would compromise his/her ability give inform consent , participate fully study , prevent adherence requirement study protocol 8 . Evidence unstable cardiovascular disease include intermittent atrial fibrillation unstable angina within 4 week prior screen 9 . History myocardial infarction , coronary artery bypass graft surgery , percutaneous cardiac intervention within last 3 month 10 . Clinically significant valvular heart disease opinion Investigator 11 . History cerebrovascular accident transient ischemic attack within last 3 month 12 . Presence history malignancy require significant medical intervention within precede 3 month and/or likely result death within next 2 year 13 . Chronic renal impairment renal insufficiency define serum creatinine Â³ 2.5 mEq/dL and/or requirement dialysis 14 . The subject lactating , breastfeeding , pregnant 15 . The subject receive investigational medication within 30 day prior start study schedule receive another investigational drug course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cicletanine</keyword>
	<keyword>Magnesium</keyword>
	<keyword>Metabolic disease</keyword>
</DOC>